Overview

A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

Summary

To determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and recommended Phase 2 dose (RP2D) of FF-10850 (topotecan liposome injection) in patients with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Fujifilm Pharmaceuticals U.S.A., Inc.

Treatments:

Topotecan